X0306 4 2020-07-17 0 0001807901 Pandion Therapeutics, Inc. PAND 0001817449 Stagliano Nancy C/O PANDION THERAPEUTICS, INC., 134 COOLIDGE AVENUE WATERTOWN MA 02472 1 0 0 0 Common Stock 2020-07-21 4 C 0 15004 A 73067 I By The Nancy E. Stagliano Trust Common Stock 2020-07-21 4 P 0 1000 18.00 A 1000 D Stock Option (right to buy) 18.00 2020-07-17 4 A 0 3674 0.00 A 2030-07-16 Common Stock 3674 3674 D Stock Option (right to buy) 18.00 2020-07-17 4 A 0 13997 0.00 A 2030-07-16 Common Stock 13997 13997 D Series A Preferred Stock 2020-07-21 4 C 0 28620 0.00 D Common Stock 5612 0 I By The Nancy E. Stagliano Trust Series B Preferred Stock 2020-07-21 4 C 0 47898 0.00 D Common Stock 9392 0 I By The Nancy E. Stagliano Trust The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Represents shares purchased through a directed share program in connection with the initial public offering of Pandion Therapeutics, Inc.'s common stock, which closed on July 21, 2020. These shares of common stock were purchased at the public offering price of $18.00 per share. This option award was granted on July 17, 2020. The shares underlying the award vest in equal quarterly installments following June 28, 2018 through June 28, 2022, subject to the reporting person's continued service on each applicable vesting date. This option award was granted on July 17, 2020. The shares underlying the award vest in equal monthly installments following July 17, 2020 through July 17, 2023, subject to the reporting person's continued service on each applicable vesting date. /s/ Edward Freedman, as attorney-in-fact for Nancy E. Stagliano 2020-07-21